This CME-certified virtual monograph based on a roundtable workshop held in New York, New York, on Saturday, January 30, 2016, with video commentary from breast cancer experts and clinical opinion poll questions, focuses on the treatment of metastatic breast cancer, specifically beyond second-line treatment.
Table of Contents
- Advanced Breast Cancer (ABC) in 2016—Current Status and Challenges
- Treatment Options in Anthracycline-Pretreated and Taxane-Pretreated ABC
- Ixabepilone in ABC: Who? When? And How?
Adam Brufsky, MD, PhD, FACPUniversity of Pittsburgh
Pittsburgh, Pennsylvania, United States
Harold J. Burstein, MD, PhDDana-Farber Cancer Institute
Boston, Massachusetts, United States
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Monica Fornier, MDMemorial Sloan Kettering Cancer Center
New York, New York, United States
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Denise Yardley, MDSarah Cannon Research Institute
Nashville, Tennessee, United States
This educational activity is specifically designed for medical oncologists, fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers who treat/manage patients with metastatic breast cancer.
After successful completion of this educational activity, participants should be able to:
- Incorporate therapies for advanced/metastatic breast cancer into individualized treatment plans for patients based upon an evaluation of efficacy and safety data, as well as patient and tumor characteristics
- Assess clinical trial data for the use of epothilones in (neo)adjuvant therapy and combinations with targeted treatment
- Identify common or significant adverse events associated with treatment of advanced/metastatic breast cancer beyond the second-line setting, and the effective strategies for their prevention and/or management
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity was approved by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center’s COA.
This activity has been approved for 1.3 contact hours.
This educational activity is supported by a grant from R-Pharm US.
March 31, 2016
October 31, 2017